By Josh White
Date: Tuesday 29 Apr 2025
(Sharecast News) - AstraZeneca delivered a strong performance in the first quarter of 2025, it announced on Tuesday, with total revenue rising 10% at constant exchange rates to $13.59bn, supported by double-digit growth in oncology and biopharmaceuticals across all major regions.
Holding(s) in Company | 29-Apr-2025 | 18:14 | RNS |
Holding(s) in Company | 29-Apr-2025 | 16:25 | RNS |
Form 8.3 ALLIANCE PHARMA PLC | 29-Apr-2025 | 15:09 | RNS |
Final Dividend Timetable | 29-Apr-2025 | 14:06 | RNS |
Form 8.3 - [ALLIANCE PHARMA PLC - 28 04 2025] - ... | 29-Apr-2025 | 12:21 | GlobeNewswire NA |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 20,553.87 |
Closing Price Change | 194.09 |
% Change | 0.95 % |
29-Apr-25 Close | 20,553.87 |
You are here: research